Wednesday, July 25, 2012

Treatment Guidelines of the US International Antiviral Society now recommend Epzicom as a preferred initial NRTI backbone regimen

In July 2012, the US International Antiviral Society updated their 2012 treatment guidelines
and are now recommending the use of Epzicom as a preferred initial NRTI backbone regimen (previously it
was recommended as an alternative option in the guidelines).
This change in the treatment guideline would push wider acceptance among HIV community and this would be further aided by the potential launch of  dolutegravir  in 2013.  Recently GSK announced clinical data which showed combination of Dolutegravir with Epzicom is superior to Atripla (a $3billion product).   1Q 2012, Epzicom grew 16% on a year over year basis.